Ventrus Biosciences Inc Share Price Nasdaq
Equities
US9228221019
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- USD | - |
Sales 2024 * | 24.2M 1.9B | Sales 2025 * | 14.52M 1.14B | Capitalization | 83.09M 6.52B |
---|---|---|---|---|---|
Net income 2024 * | -52M -4.08B | Net income 2025 * | -54M -4.23B | EV / Sales 2024 * | 3.43 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 5.72 x |
P/E ratio 2024 * |
-1.59
x | P/E ratio 2025 * |
-1.57
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 66.94% |
Latest transcript on Ventrus Biosciences Inc
Managers | Title | Age | Since |
---|---|---|---|
Jason Okazaki
CEO | Chief Executive Officer | 48 | 29/03/20 |
Anuj Gaggar
CTO | Chief Tech/Sci/R&D Officer | 46 | 11-07 |
William Delaney
CTO | Chief Tech/Sci/R&D Officer | 52 | 31/05/20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Susan Mahony
BRD | Director/Board Member | 59 | 13/12/17 |
Gina Consylman
BRD | Director/Board Member | 52 | 19/10/20 |
William Ringo
CHM | Chairman | 78 | 30/06/14 |
1st Jan change | Capi. | |
---|---|---|
+16.34% | 79.28B | |
+8.25% | 8.74B | |
-16.33% | 4.84B | |
+51.22% | 4.74B | |
+2.18% | 3.87B | |
+20.51% | 2.46B | |
-26.79% | 2.18B | |
+15.12% | 2.09B | |
-36.56% | 1.98B |